BioArctic AB 2020 AR2
The report highlights BioArctic's progress in 2020, focusing on developing disease-modifying treatments for central nervous system disorders like Alzheimer's and Parkinson's diseases. Key achievements include the advancement of the drug candidate lecanemab (BAN2401) into a new global Phase 3 program (AHEAD 3-45) and continued progress in the Clarity AD Phase 3 study. Additionally, the company was awarded the 2020 Allbright Prize for its outstanding gender equality initiatives, achieving an even gender distribution across the organization. Financially, BioArctic maintained a strong position with cash and cash equivalents of SEK 1,000 million at year-end, despite reporting an operating loss of MSEK 85.0 due to the timing of milestone payments.
Company: BioArctic AB
Sector: Professional & technical services
Country: Sweden
Year: 2020
Type: AR2
Pages: 110
Back to company
BioArctic AB
Annual Report
The report highlights BioArctic's progress in 2020, focusing on developing disease-modifying treatments for central nervous system disorders like Alzheimer's and Parkinson's diseases. Key achievements include the advancement of the drug candidate lecanemab (BAN2401) into a new global Phase 3 program (AHEAD 3-45) and continued progress in the Clarity AD Phase 3 study. Additionally, the company was awarded the 2020 Allbright Prize for its outstanding gender equality initiatives, achieving an even gender distribution across the organization. Financially, BioArctic maintained a strong position with cash and cash equivalents of SEK 1,000 million at year-end, despite reporting an operating loss of MSEK 85.0 due to the timing of milestone payments.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees